Suppr超能文献

肛门缘鳞状细胞癌:佛罗里达大学的经验。

Squamous cell carcinoma of the anal margin: the university of Florida experience.

机构信息

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, 32610–0385, USA.

出版信息

Am J Clin Oncol. 2011 Aug;34(4):406-10. doi: 10.1097/COC.0b013e3181e9c0c0.

Abstract

OBJECTIVE

To update our experience in treating squamous cell carcinoma of the anal margin with definitive radiotherapy (RT).

METHODS

A total of 26 patients treated curatively with RT between 1979 and 2008, with or without concurrent chemotherapy, were retrospectively reviewed. American Joint Committee on Cancer stage distribution was: T1, N = 1; T2, N = 16; T3, N = 9; N0, N = 25; and N1, N = 1. Concurrent chemotherapy was administered in 12 of 26 patients (T2, 19%; T3, 100%). Median age was 48.5 years (range, 31-84 years) with a median follow-up of 8.4 years (range, 0.9-16.1 years). Median total dose was 59.4 Gy in 33 fractions. Elective inguinal lymph-node irradiation was administered to 23 of 25 N0 patients.

RESULTS

The 10-year cause-specific survival, disease-free survival, and overall survival were 92%, 88%, and 56%, respectively. Of the 26 patients, 24 experienced complete tumor regression; their local-control rate was 96%. Four patients developed recurrences (1 local, 2 regional, and 1 local/regional/distant). The 2 patients who did not receive elective inguinal lymph-node irradiation recurred in this region. Ten patients died of intercurrent disease between 2.0 and 15.9 years after RT. Two patients died with disease at 10.7 and 18.2 months after RT, whereas 1 patient is alive with local disease at 11.2 years after RT. The remaining 13 patients are alive and disease-free between 1.0 and 16.1 years after RT. The anal-sphincter-preservation rate was 88% with no severe long-term complications after RT.

CONCLUSIONS

Patients with squamous cell carcinoma of the anal margin have a high probability of cure with sphincter preservation after RT with or without concurrent chemotherapy.

摘要

目的

更新我们使用根治性放疗(RT)治疗肛门边缘鳞状细胞癌的经验。

方法

回顾性分析 1979 年至 2008 年间接受 RT 治疗的 26 例患者的资料,其中部分患者接受了同步放化疗。美国癌症联合委员会(AJCC)分期分布如下:T1 期,N=1;T2 期,N=16;T3 期,N=9;N0 期,N=25;N1 期,N=1。26 例患者中有 12 例(T2 期占 19%,T3 期占 100%)接受了同步放化疗。中位年龄为 48.5 岁(范围 31-84 岁),中位随访时间为 8.4 年(范围 0.9-16.1 年)。中位总剂量为 59.4 Gy,共 33 次。25 例 N0 患者中有 23 例接受了选择性腹股沟淋巴结照射。

结果

10 年的疾病特异性生存率、无病生存率和总生存率分别为 92%、88%和 56%。26 例患者中,24 例肿瘤完全消退,局部控制率为 96%。4 例患者复发(1 例局部,2 例区域,1 例局部/区域/远处)。未行选择性腹股沟淋巴结照射的 2 例患者在该区域复发。10 例患者在 RT 后 2.0-15.9 年内死于并发疾病。2 例患者在 RT 后 10.7 和 18.2 个月死于疾病,1 例患者在 RT 后 11.2 年仍有局部疾病存活。其余 13 例患者在 RT 后 1.0-16.1 年内存活且无疾病。RT 后保留肛门括约肌的比例为 88%,无严重的长期并发症。

结论

接受同步放化疗或单纯 RT 治疗的肛门边缘鳞状细胞癌患者保留肛门括约肌后有很高的治愈概率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验